These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26864802)

  • 1. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
    Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
    Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons.
    Martin NK; Hickman M; Miners A; Hutchinson SJ; Taylor A; Vickerman P
    BMJ Open; 2013 Aug; 3(8):. PubMed ID: 23943776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
    He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
    Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation.
    Martin NK; Vickerman P; Dore GJ; Grebely J; Miners A; Cairns J; Foster GR; Hutchinson SJ; Goldberg DJ; Martin TCS; Ramsay M; ; Hickman M
    J Hepatol; 2016 Jul; 65(1):17-25. PubMed ID: 26867489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
    Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
    Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
    Marquez LK; Fleiz C; Burgos JL; Cepeda JA; McIntosh C; Garfein RS; Kiene SM; Brodine S; Strathdee SA; Martin NK
    Addiction; 2021 Oct; 116(10):2734-2745. PubMed ID: 33620750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
    Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
    Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective.
    Buchanan R; Cooper K; Grellier L; Khakoo SI; Parkes J
    J Viral Hepat; 2020 Jan; 27(1):36-44. PubMed ID: 31520434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination.
    Shih STF; Stone J; Martin NK; Hajarizadeh B; Cunningham EB; Kwon JA; McGrath C; Grant L; Grebely J; Dore GJ; Lloyd AR; Vickerman P; Chambers GM
    Open Forum Infect Dis; 2024 Feb; 11(2):ofad637. PubMed ID: 38344130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of strategies to improve HCV screening, linkage-to-care and treatment in remand prison settings in England.
    Mohamed Z; Scott N; Al-Kurdi D; Selvapatt N; Thursz MR; Lemoine M; Brown AS; Nayagam S
    Liver Int; 2020 Dec; 40(12):2950-2960. PubMed ID: 32750192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
    Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention.
    Martin NK; Vickerman P; Dore GJ; Hickman M
    Curr Opin HIV AIDS; 2015 Sep; 10(5):374-80. PubMed ID: 26248124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands.
    van Santen DK; de Vos AS; Matser A; Willemse SB; Lindenburg K; Kretzschmar ME; Prins M; de Wit GA
    PLoS One; 2016; 11(10):e0163488. PubMed ID: 27711200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
    Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
    J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
    Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
    Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.